Connection

Peter Jüni to Myocardial Infarction

This is a "connection" page, showing publications Peter Jüni has written about Myocardial Infarction.
Connection Strength

0.396
  1. Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. Eur Heart J. 2019 08 14; 40(31):2595-2604.
    View in: PubMed
    Score: 0.063
  2. 2018 ESC/EACTS Guidelines on myocardial revascularization. EuroIntervention. 2019 Feb 20; 14(14):1435-1534.
    View in: PubMed
    Score: 0.061
  3. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018 09 15; 392(10151):940-949.
    View in: PubMed
    Score: 0.059
  4. The Compare-Acute trial of fractional flow reserve-guided multivessel angioplasty in myocardial infarction. EuroIntervention. 2017 08 04; 13(5):e613-e616.
    View in: PubMed
    Score: 0.055
  5. Impact of stent overlap on long-term clinical outcomes in patients treated with newer-generation drug-eluting stents. EuroIntervention. 2014 Jan 22; 9(9):1076-84.
    View in: PubMed
    Score: 0.043
  6. Restrictive compared with liberal red cell transfusion strategies in cardiac surgery: a meta-analysis. Eur Heart J. 2019 04 01; 40(13):1081-1088.
    View in: PubMed
    Score: 0.015
  7. Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data. Eur Heart J. 2019 01 07; 40(2):180-186.
    View in: PubMed
    Score: 0.015
  8. Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. Lancet. 2018 09 01; 392(10149):737-746.
    View in: PubMed
    Score: 0.015
  9. Six-Month Outcomes after Restrictive or Liberal Transfusion for Cardiac Surgery. N Engl J Med. 2018 09 27; 379(13):1224-1233.
    View in: PubMed
    Score: 0.015
  10. Five-Year Outcomes with PCI Guided by Fractional Flow Reserve. N Engl J Med. 2018 07 19; 379(3):250-259.
    View in: PubMed
    Score: 0.014
  11. Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes. Eur Heart J. 2017 Dec 14; 38(47):3493-3502.
    View in: PubMed
    Score: 0.014
  12. Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery. N Engl J Med. 2017 11 30; 377(22):2133-2144.
    View in: PubMed
    Score: 0.014
  13. Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis. Eur J Cardiothorac Surg. 2017 Aug 01; 52(2):206-217.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.